Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020.

BACKGROUND: Drug persistence is a crucial aspect of treatment success in psoriasis. OBJECTIVES: The scope of this manuscript is to record real-world evidence concerning drug survival of biologic agents used for psoriasis treatment and to detect associated modifying factors in Greece. METHODS: This was a retrospective cohort study based on data extracted from the nationwide Greek prescription system. Psoriatic patients, with or without concomitant psoriatic arthritis (PsA), that had initiated biologics between January 1st 2016 and December 31st 2020 were included. RESULTS: We included 8,819 patients who received 13,359 treatment lines. Among them, 76.8% were biologic naïve patients and 16.5% were diagnosed with concomitant PsA. The overall median drug survival was 34.3 (95% CI: 32.6-36.5) months. Drug persistence at 12, 24, 36 and 48 months of follow-up was 71.9%, 57.7%, 49.0% and 43.7%, respectively. Patients receiving brodalumab had the highest drug survival rate in the first two years, while secukinumab had the highest rates beyond this period. Overall, drug survival rates were higher in the 1st [median, 51.1 (95% CI: 47.1, not reached (NR) months] compared to the 2nd treatment line and onwards [median, 21.7 (95% CI: 20.0, 23.5) months]. Treatment line, PsA status, age and sex were found to significantly affect drug survival rates. CONCLUSIONS: Our findings confirm previous reports regarding the importance of efficient 1st line biologics and the vulnerability of patients to co-existent PsA. The utilitzation of antibodies against interleukins confer to high drug survival rates. These results will assist clinical management of psoriasis patients in Greece.

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.

Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. After a dose-escalated phase 1 safety study, 90 participants were randomized to receive CoV-2-ST+SoC (n = 60) or SoC only (n = 30). The co-primary objectives of the study were the composite of time to recovery and 30-d recovery rate and the in vivo expansion of CoV-2-STs in patients receiving CoV-2-ST+SoC over SoC. The key secondary objective was survival on day 60. CoV-2-ST+SoC treatment was safe and well tolerated. The study met the primary composite endpoint (CoV-2-ST+SoC versus SoC: recovery rate 65% versus 38%, P = 0.017; median recovery time 11 d versus not reached, P = 0.052, respectively; rate ratio for recovery 1.71 (95% confidence interval 1.03-2.83, P = 0.036)) and the co-primary objective of significant CoV-2-ST expansion compared to SοC (CoV-2-ST+SoC versus SoC, P = 0.047). Overall, in hospitalized patients with severe COVID-19, adoptive immunotherapy with CoV-2-STs was feasible and safe. Larger trials are needed to strengthen the preliminary evidence of clinical benefit in severe COVID-19. EudraCT identifier: 2021-001022-22 .

The Acute Effects of Static Stretching on Speed and Agility Performance Depend on Stretch Duration and Conditioning Level.

Avloniti, A, Chatzinikolaou, A, Fatouros, IG, Avloniti, C, Protopapa, M, Draganidis, D, Stampoulis, T, Leontsini, D, Mavropalias, G, Gounelas, G, and Kambas, A. The acute effects of static stretching on speed and agility performance depend on stretch duration and conditioning level. J Strength Cond Res 30(10): 2767-2773, 2016-Although static stretching (SS) is an integral part of physical preparation before training and competition, its usefulness in regards to power performance improvement has been questioned. The aim of this study was to investigate the effect of 6 SS durations on speed and agility performance. According to a cross-over design, 34 trained men (age, 20.5 ± 1.4 years; height, 1.81 ± 0.2 m; weight, 77.2 ± 2.6 kg; body fat, 8.2 ± 2.6%) participated in a control session (no stretch) and 6 experimental conditions (10, 15, 20, 30, 40, and 60 seconds) performed in a randomized order. Performance in speed (10 and 20 m) and agility (T-test) was measured after the control and experimental conditions. Static stretching, consisting of stretches for hip extensors, hip adductors, knee extensors, knee flexors, and ankle sole flexors, was performed after light cardiovascular exercise (8 minutes). A 1-way repeated-measures analysis of variance showed that speed was improved only by SS of short duration (15/20 seconds), whereas agility remained unaffected by all SS trials. When participants' speed and agility level was taken into account, it was revealed that only those of moderate performance demonstrated an improved speed (in 15- and 20-second trials) and agility (in 10- and 15-second trials) performance. These results suggest that short-duration SS protocols induce an acute improvement of speed and agility performance, whereas longer-duration SS protocols have neither positive nor negative effect. Furthermore, it seems that individuals of lower speed and agility performance level are more likely to benefit by a short-duration SS protocol.